haloperidol has been researched along with Parkinson Disease, Secondary in 130 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to determine whether L-701,324 [7-chloro-4-hydroxy-3(3-phenoxy) phenylquinoline-2-(H)-one], a selective and full antagonist at the glycine site of the NMDA receptor, counteracts parkinsonian-like muscle rigidity and catalepsy induced by haloperidol in rats." | 7.70 | L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats. ( Coper, H; Konieczny, J; Ossowska, K; Schulze, G; Wolfarth, S, 1999) |
| "The aim of the present study was to assess the efficacy of pramipexole (2-amino-4,5,6, 7-tetrahydro-6-propyl-amino-benzthiazole-dihydrochloride), a new dopamine D(2)/D(3) receptor agonist, to attenuate parkinsonian-like muscle rigidity in rats." | 7.70 | Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. ( Lorenc-Koci, E; Wolfarth, S, 1999) |
| " Oscillations in forelimb force during this performance were spectrally analyzed to describe the tremorogenic effects of haloperidol (0." | 7.68 | A new rodent model for neuroleptic-induced pseudo-parkinsonism: low doses of haloperidol increase forelimb tremor in the rat. ( Fowler, SC; Liao, RM; Skjoldager, P, 1990) |
| "Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized." | 4.79 | Safety of olanzapine. ( Beasley, CM; Tollefson, GD; Tran, PV, 1997) |
| "This is a review of reserpine, haloperidol, and various phenothiazines that produce parkinsonism and other movement disorders." | 4.78 | Drug-induced parkinsonism and other movement disorders. ( Ross, RT, 1990) |
| "The aim of this study was to determine whether L-701,324 [7-chloro-4-hydroxy-3(3-phenoxy) phenylquinoline-2-(H)-one], a selective and full antagonist at the glycine site of the NMDA receptor, counteracts parkinsonian-like muscle rigidity and catalepsy induced by haloperidol in rats." | 3.70 | L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats. ( Coper, H; Konieczny, J; Ossowska, K; Schulze, G; Wolfarth, S, 1999) |
| "The aim of the present study was to assess the efficacy of pramipexole (2-amino-4,5,6, 7-tetrahydro-6-propyl-amino-benzthiazole-dihydrochloride), a new dopamine D(2)/D(3) receptor agonist, to attenuate parkinsonian-like muscle rigidity in rats." | 3.70 | Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. ( Lorenc-Koci, E; Wolfarth, S, 1999) |
| " Oscillations in forelimb force during this performance were spectrally analyzed to describe the tremorogenic effects of haloperidol (0." | 3.68 | A new rodent model for neuroleptic-induced pseudo-parkinsonism: low doses of haloperidol increase forelimb tremor in the rat. ( Fowler, SC; Liao, RM; Skjoldager, P, 1990) |
| "Baclofen, commonly used to reduce severe muscle spasms in patients with spinal cord injuries, is also active in the brain." | 3.66 | A possible neurochemical basis for the neuropsychiatric aspects of baclofen therapy. ( Keegan, DL; Kirby, AR; Richardson, JS, 1983) |
| "26 patients with a paranoid-hallucinatory syndrome were treated with a fixed daily dose of haloperidol." | 3.65 | Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol. ( Ackenheil, M; Eben, E; Hippius, H; Rüther, E; Schilkrut, R, 1976) |
| "The authors conducted a multicenter, double-blind, placebo-controlled, randomized trial of flexibly dosed quetiapine and haloperidol." | 2.72 | Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. ( Copenhaver, M; Katz, IR; Mintzer, JE; Schneider, L; Street, J; Tariot, PN; Williams-Hughes, C, 2006) |
| "During long-term treatment of schizophrenia with antipsychotic medication, side effects such as weight gain and tardive dyskinesia may develop, while other extrapyramidal side effects may continue." | 2.67 | Side effects during long-term treatment with depot antipsychotic medication. ( Cookson, JC, 1991) |
| "Most traditional neuroleptics have a narrow therapeutic-to-toxic index, and thus, the novel antipsychotics are the result of a search to substantially widen the distance between the dose that treats psychosis and the one that produces adverse effects." | 2.40 | The relationship of pharmacology to side effects. ( Casey, DE, 1997) |
| "This report attempts to highlight that use of an antipsychotic and concurrent chronic use of methamphetamine can cause drug-induced parkinsonism." | 1.42 | Drug-induced parkinsonism following chronic methamphetamine use by a patient on haloperidol decanoate. ( Gedzior, JS; Matthew, BJ, 2015) |
| "Rats treated with haloperidol at doses of 0." | 1.37 | Reversal of haloperidol-induced motor deficits by mianserin and mesulergine in rats. ( Haleem, DJ; Shireen, E, 2011) |
| " A similar dose-response relationship was determined for nifedipine, an L-type calcium channel antagonist." | 1.31 | Pharmacological involvement of the calcium channel blocker flunarizine in dopamine transmission at the striatum. ( Armando, I; Belforte, JE; Buño, W; Magariños-Azcone, C; Pazo, JH, 2001) |
| "Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors." | 1.30 | Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. ( Heinz, A; Knable, MB; Raedler, T; Weinberger, DR, 1997) |
| " After chronic haloperidol dosing (vehicle, 0." | 1.30 | Chronic haloperidol produces a time- and dose-related slowing of lick rhythm in rats: implications for rodent models of tardive dyskinesia and neuroleptic-induced parkinsonism. ( Fowler, SC; Wang, G, 1998) |
| "Haloperidol-induced catalepsy was inhibited by the Merz glycine site antagonists MRZ 2/570, MRZ 2/571 and MRZ 2/576 but not by another antagonist L-701,324 or the glycine site partial agonists ACPC and D-CS." | 1.30 | GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist. ( Danysz, W; Karcz-Kubicha, M; Lorenz, B, 1999) |
| "However, the severity of the catalepsy score following the third through seventh injections of haloperidol strongly correlated with the concurrent number of VCMs." | 1.29 | Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate. ( Egan, MF; Hyde, TM; Kleinman, JE; Weinberger, DR; Wing, LL; Wyatt, RJ, 1995) |
| "Pretreatment with haloperidol suppressed both the antiparkinsonian effects and the hyperactivity induced by apomorphine." | 1.29 | Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys. ( Akai, T; Kuno, S; Mizuta, E; Yamaguchi, M, 1993) |
| "Haloperidol was administered to rabbits in a dose 500 micrograms/kg during 60 min or 30 days." | 1.29 | [The mechanism of the pathogenesis of drug-induced parkinsonism (experimental biochemical and bioelectrical research on the action of haloperidol)]. ( Dovedova, EL; Popova, NS, 1993) |
| " In contrast, chronic administration of the D1-like receptor agonist CY 208243 to 6-OHDA-lesioned rats dramatically enhanced deltaFosB-like immunoreactivity in striatal neurons projecting to the substantia nigra." | 1.29 | Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. ( Bedard, PJ; Blanchet, P; Chen, JS; Doucet, JP; Grondin, R; Hope, BT; Iadarola, MJ; Jasmin, BJ; Nakabeppu, Y; Nestler, EJ; Robertson, GS; St-Jean, M; Wigle, N, 1996) |
| "Haloperidol was found to have a similar metabolic pathway to that of the neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice microsomal preparations." | 1.28 | Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite. ( Fang, J; Gorrod, JW, 1991) |
| "Haloperidol was implicated in 47 patients (37%), followed by amitriptyline/perphenazine in 30%, thioridazine in 27%, and chlorpromazine in 20%." | 1.28 | Neurologic approach to drug-induced movement disorders: a study of 125 patients. ( Jankovic, J; Miller, LG, 1990) |
| " An increase in dosage also had only a transient effect." | 1.27 | Development of tolerance to the therapeutic effect of amantadine on akathisia. ( Barreira, P; Lipinski, JF; Zubenko, GS, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 64 (49.23) | 18.7374 |
| 1990's | 42 (32.31) | 18.2507 |
| 2000's | 12 (9.23) | 29.6817 |
| 2010's | 9 (6.92) | 24.3611 |
| 2020's | 3 (2.31) | 2.80 |
| Authors | Studies |
|---|---|
| Olaya, MDP | 1 |
| Vergel, NE | 1 |
| López, JL | 1 |
| Viña, MD | 1 |
| Guerrero, MF | 1 |
| Saleem, U | 3 |
| Raza, Z | 1 |
| Anwar, F | 3 |
| Chaudary, Z | 1 |
| Ahmad, B | 3 |
| Bhattamisra, SK | 1 |
| Shak, AT | 1 |
| Xi, LW | 1 |
| Safian, NH | 1 |
| Choudhury, H | 1 |
| Lim, WM | 1 |
| Shahzad, N | 1 |
| Alhakamy, NA | 1 |
| Anwer, MK | 1 |
| Radhakrishnan, AK | 1 |
| Md, S | 1 |
| Sanawar, M | 1 |
| Nazir, S | 1 |
| Akhtar, MF | 1 |
| Ismail, T | 1 |
| Parambi, DGT | 1 |
| Shah, MA | 1 |
| Manzar, A | 1 |
| Itzaz, A | 1 |
| Harilal, S | 1 |
| Uddin, MS | 1 |
| Kim, H | 1 |
| Mathew, B | 1 |
| Shireen, E | 3 |
| Naeem, S | 1 |
| Inam, QU | 1 |
| Haleem, DJ | 3 |
| Politis, AM | 1 |
| Kokras, N | 1 |
| Pappa, D | 1 |
| Siarkos, C | 1 |
| Katirtzoglou, E | 1 |
| Papadimitriou, GN | 1 |
| Kahn, DA | 1 |
| Pervez, S | 1 |
| Masroor, M | 1 |
| Ali, WB | 1 |
| Rais, Q | 1 |
| Khalil, S | 1 |
| Tariq, A | 1 |
| Matthew, BJ | 1 |
| Gedzior, JS | 1 |
| Greco, B | 1 |
| Lopez, S | 1 |
| van der Putten, H | 1 |
| Flor, PJ | 1 |
| Amalric, M | 1 |
| Glavina, T | 1 |
| Mrass, D | 1 |
| Dodig, T | 1 |
| Glavina, G | 1 |
| Pranić, S | 1 |
| Uglešić, B | 1 |
| Schmidt, WJ | 1 |
| Mayerhofer, A | 1 |
| Meyer, A | 1 |
| Kovar, KA | 1 |
| Cohen, CI | 1 |
| Schoos, R | 1 |
| Wang, S | 1 |
| Hu, LF | 1 |
| Yang, Y | 1 |
| Ding, JH | 1 |
| Hu, G | 1 |
| Ulrich, S | 1 |
| Sandmann, U | 1 |
| Genz, A | 1 |
| Tariot, PN | 1 |
| Schneider, L | 1 |
| Katz, IR | 1 |
| Mintzer, JE | 1 |
| Street, J | 1 |
| Copenhaver, M | 1 |
| Williams-Hughes, C | 1 |
| Schuster, JP | 1 |
| Buhl, C | 1 |
| Archambaud, F | 1 |
| Hardy, P | 1 |
| Chouinard, G | 2 |
| Prigent, A | 1 |
| Corruble, E | 1 |
| Johnson, PC | 1 |
| Charalampous, KD | 1 |
| Braun, GA | 1 |
| Rubin, RT | 1 |
| Hays, SE | 1 |
| Ringwald, E | 1 |
| Lustig, A | 1 |
| Moscovici, M | 1 |
| Spiegel, R | 1 |
| Vamos, E | 1 |
| Bowers, MB | 2 |
| Heninger, GR | 2 |
| Rajput, AH | 1 |
| Rozdilsky, B | 1 |
| Hornykiewicz, O | 1 |
| Shannak, K | 1 |
| Lee, T | 1 |
| Seeman, P | 1 |
| Keegan, DL | 1 |
| Richardson, JS | 1 |
| Kirby, AR | 1 |
| Munk-Andersen, E | 1 |
| Behnke, K | 1 |
| Heltberg, J | 1 |
| Nielsen, H | 1 |
| Gerlach, J | 5 |
| Schmidt, LG | 1 |
| Grohmann, R | 1 |
| Helmchen, H | 1 |
| Langscheid-Schmidt, K | 1 |
| Müller-Oerlinghausen, B | 1 |
| Poser, W | 1 |
| Rüther, E | 3 |
| Scherer, J | 1 |
| Strauss, A | 1 |
| Wolf, B | 1 |
| Zubenko, GS | 1 |
| Barreira, P | 1 |
| Lipinski, JF | 1 |
| Gómez, EA | 1 |
| Holcomb, HH | 1 |
| Sternberg, DE | 1 |
| Gomirato, G | 1 |
| Hydén, H | 1 |
| Mussini, E | 1 |
| Rönnbäck, L | 1 |
| Caine, ED | 1 |
| Denijs, EL | 1 |
| Johnels, B | 1 |
| Steg, G | 1 |
| Moleman, P | 2 |
| Schmitz, PJ | 1 |
| Ladee, GA | 1 |
| Verma, A | 1 |
| Kulkarni, SK | 1 |
| McSwain, ML | 1 |
| Forman, LM | 1 |
| Hyde, TM | 1 |
| Egan, MF | 1 |
| Wing, LL | 1 |
| Wyatt, RJ | 1 |
| Weinberger, DR | 2 |
| Kleinman, JE | 1 |
| Gewirtz, GR | 1 |
| Sharif, Z | 1 |
| Cadet, JL | 1 |
| Sarti, P | 1 |
| Gorman, JM | 1 |
| Richard, MG | 1 |
| Bennett, JP | 1 |
| Akai, T | 1 |
| Yamaguchi, M | 1 |
| Mizuta, E | 1 |
| Kuno, S | 1 |
| Dovedova, EL | 1 |
| Popova, NS | 1 |
| Byerly, MJ | 1 |
| Christensen, RC | 1 |
| Evans, OL | 1 |
| Doucet, JP | 1 |
| Nakabeppu, Y | 1 |
| Bedard, PJ | 1 |
| Hope, BT | 1 |
| Nestler, EJ | 1 |
| Jasmin, BJ | 1 |
| Chen, JS | 1 |
| Iadarola, MJ | 1 |
| St-Jean, M | 1 |
| Wigle, N | 1 |
| Blanchet, P | 1 |
| Grondin, R | 1 |
| Robertson, GS | 1 |
| Northoff, G | 1 |
| Wenke, J | 1 |
| Pflug, B | 1 |
| Pavletic, ZS | 1 |
| Bishop, MR | 1 |
| Markopoulou, K | 1 |
| Wszolek, ZK | 1 |
| Maany, I | 2 |
| Schneider, JS | 1 |
| Dhopesh, V | 1 |
| Macfadden, A | 1 |
| Gamble, G | 1 |
| Beasley, CM | 1 |
| Tollefson, GD | 1 |
| Tran, PV | 1 |
| Casey, DE | 3 |
| Blitzstein, SM | 1 |
| Brandt, GT | 1 |
| Knable, MB | 1 |
| Heinz, A | 1 |
| Raedler, T | 1 |
| Caligiuri, MP | 1 |
| Rockwell, E | 1 |
| Jeste, DV | 1 |
| Hashitani, T | 1 |
| Mizukawa, K | 1 |
| Kumazaki, M | 1 |
| Nishino, H | 1 |
| Fowler, SC | 2 |
| Wang, G | 1 |
| Mazurek, MF | 1 |
| Savedia, SM | 1 |
| Bobba, RS | 1 |
| Garside, S | 1 |
| Rosebush, PI | 1 |
| Iakimovskiĭ, AF | 1 |
| Cardoso, F | 1 |
| Camargos, ST | 1 |
| Silva Júnior, GA | 1 |
| Black, KJ | 1 |
| Racette, B | 1 |
| Perlmutter, JS | 1 |
| Yamakawa, T | 1 |
| Ohta, S | 1 |
| Karcz-Kubicha, M | 1 |
| Lorenz, B | 1 |
| Danysz, W | 1 |
| Gomberg, RF | 1 |
| Konieczny, J | 1 |
| Ossowska, K | 1 |
| Schulze, G | 1 |
| Coper, H | 1 |
| Wolfarth, S | 2 |
| Lorenc-Koci, E | 1 |
| Bulling, M | 1 |
| Miwa, H | 1 |
| Nishi, K | 1 |
| Fuwa, T | 1 |
| Mizuno, Y | 1 |
| Steece-Collier, K | 1 |
| Chambers, LK | 1 |
| Jaw-Tsai, SS | 1 |
| Menniti, FS | 1 |
| Greenamyre, JT | 1 |
| Sawada, Y | 1 |
| Nasu, R | 1 |
| Matsuo, H | 1 |
| Ohtani, H | 1 |
| Iwahashi, K | 1 |
| Anemo, K | 1 |
| Nakamura, K | 1 |
| Yoshihara, E | 1 |
| Igarashi, K | 1 |
| Antkiewicz-Michaluk, L | 1 |
| Michaluk, J | 1 |
| Romańska, I | 1 |
| Papla, I | 1 |
| Vetulani, J | 1 |
| Belforte, JE | 1 |
| Magariños-Azcone, C | 1 |
| Armando, I | 1 |
| Buño, W | 1 |
| Pazo, JH | 1 |
| Diamond, BI | 1 |
| Borison, RL | 1 |
| Pérez de Francisco, C | 1 |
| Garnica Portillo, R | 1 |
| Simmelsgaard, H | 1 |
| Corsini, GU | 1 |
| Del Zompo, M | 1 |
| Spissu, A | 1 |
| Mangoni, A | 1 |
| Gessa, GL | 1 |
| Martin, IC | 1 |
| Wildbolz, A | 1 |
| Raskind, M | 1 |
| Alvarez, C | 1 |
| Herlin, S | 1 |
| Ule, G | 1 |
| Struwe, O | 1 |
| Gunne, LM | 1 |
| Bárány, S | 1 |
| De Fraites, EG | 1 |
| Davis, KL | 1 |
| Berger, PA | 1 |
| Gelenberg, AJ | 1 |
| Mandel, MR | 1 |
| Schilkrut, R | 2 |
| Ackenheil, M | 2 |
| Eben, E | 2 |
| Hippius, H | 2 |
| Ayd, FJ | 1 |
| Thorsen, K | 1 |
| Fog, R | 1 |
| Avakian, RM | 1 |
| Dutov, AA | 1 |
| Parkhomenko, VM | 1 |
| Mierau, J | 1 |
| Schingnitz, G | 1 |
| Lauterbach, EC | 1 |
| Jicha, GA | 1 |
| Salamone, JD | 1 |
| Cookson, JC | 1 |
| Fang, J | 1 |
| Gorrod, JW | 1 |
| Lublin, H | 1 |
| Hagert, U | 1 |
| Meidahl, B | 1 |
| Mølbjerg, C | 1 |
| Pedersen, V | 1 |
| Rendtorff, C | 1 |
| Tolvanen, E | 1 |
| Miller, LG | 1 |
| Jankovic, J | 1 |
| Ross, RT | 1 |
| Carvey, PM | 1 |
| McRae, A | 1 |
| Ptak, LR | 1 |
| Kao, LC | 1 |
| Lo, ES | 1 |
| Goetz, CG | 1 |
| Tanner, CM | 1 |
| Penn, RD | 1 |
| Klawans, HL | 2 |
| Liao, RM | 1 |
| Skjoldager, P | 1 |
| Altamura, AC | 1 |
| Mauri, MC | 1 |
| De Novellis, F | 1 |
| Percudani, M | 1 |
| Vampini, V | 1 |
| Arushanian, EB | 2 |
| Bulens, C | 1 |
| Meerwaldt, JD | 1 |
| van der Wildt, GJ | 1 |
| Keemink, CJ | 1 |
| Hoffman, AS | 1 |
| Schwartz, HI | 1 |
| Novick, RM | 1 |
| Bateman, DN | 1 |
| Rawlins, MD | 1 |
| Simpson, JM | 1 |
| Bissonnette, B | 1 |
| Janzen, G | 1 |
| von Bargen, BA | 1 |
| Kappers, EJ | 1 |
| Pepplinkhuizen, L | 1 |
| Schmitz, PI | 1 |
| Aoba, A | 1 |
| Kakita, Y | 1 |
| Yamaguchi, N | 1 |
| Shido, M | 1 |
| Tsuneizumi, T | 1 |
| Shibata, M | 1 |
| Kitani, K | 1 |
| Hasegawa, K | 1 |
| Aronson, TA | 1 |
| Sandyk, R | 1 |
| Vogt, M | 2 |
| Bruck, H | 1 |
| Gerstenbrand, F | 1 |
| Gnad, H | 1 |
| Gründig, E | 1 |
| Prosenz, P | 1 |
| Bordeleau, JM | 1 |
| Tétreault, L | 1 |
| Itil, TM | 1 |
| Patterson, CD | 1 |
| Keskiner, A | 1 |
| Holden, JM | 1 |
| De Maio, D | 1 |
| O'Keeffe, R | 1 |
| Sharman, DF | 1 |
| Nose, T | 1 |
| Kojima, M | 1 |
| Ishida, R | 1 |
| Shintomi, K | 1 |
| Kowa, Y | 1 |
| Demars, JP | 1 |
| Bruno, A | 1 |
| Bruno, SC | 1 |
| Nehlil, J | 1 |
| Zolotnitskii, RI | 1 |
| Kutsenok, BM | 1 |
| Gastev, MD | 1 |
| Ridges, AP | 1 |
| Harper, P | 1 |
| Kivalo, E | 1 |
| Weckman, N | 1 |
| Stoliarov, GV | 1 |
| Tolpyshev, BA | 1 |
| Immich, H | 1 |
| Eckmann, F | 1 |
| Neumann, H | 1 |
| Schäpperle, O | 1 |
| Schwarz, H | 1 |
| Tempel, H | 1 |
| Prasad, L | 1 |
| Townley, MC | 1 |
| Ekdawi, MY | 1 |
| Fowke, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Blood Lactate Levels in Patients Treated With Typical or Atypical Antipsychotics[NCT01139463] | 60 participants (Actual) | Observational | 2008-06-30 | Completed | |||
| A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936] | Phase 4 | 16 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| I-123 Iodobenzamide (IBZM) SPECT Studies of D2 Receptor Distribution and Function in Patients With Schizophrenia and Normal Volunteers[NCT00001320] | 265 participants | Observational | 1991-10-31 | Completed | |||
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.4 |
| Placebo | 0.3 |
Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -3 |
| Placebo | 9 |
Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | 0.4 |
| Placebo | 0.6 |
Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -0.2 |
| Placebo | 3.1 |
Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -51.7 |
| Placebo | 47.6 |
Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | cm (Mean) |
|---|---|
| Aripiprazole | 0.0 |
| Placebo | 0.0 |
Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | lbs (Mean) |
|---|---|
| Aripiprazole | -2.9 |
| Placebo | 2.1 |
8 reviews available for haloperidol and Parkinson Disease, Secondary
| Article | Year |
|---|---|
The prolactin secretory response to neuroleptic drugs: mechanisms, applications and limitations.
Topics: Animals; Antipsychotic Agents; Blood-Brain Barrier; Cerebral Cortex; Chlorpromazine; Dopamine; Drug | 1980 |
Safety of olanzapine.
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Clini | 1997 |
The relationship of pharmacology to side effects.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; D | 1997 |
[Diagnostic errors due to unilateral psychiatric or unilateral somatic appreciation (author's transl)].
Topics: Adjustment Disorders; Adult; Aged; Brain Neoplasms; Bronchial Neoplasms; Diagnostic Errors; Echinoco | 1979 |
Drug-induced parkinsonism and other movement disorders.
Topics: Haloperidol; Humans; Movement Disorders; MPTP Poisoning; Parkinson Disease, Secondary; Phenothiazine | 1990 |
[Neuroleptic parkinsonism and tardive dyskinesia and methods of pharmacologically correcting these pathologic conditions (review)].
Topics: Animals; Antipsychotic Agents; Cats; Cholinergic Fibers; Corpus Striatum; Dopamine; Dyskinesia, Drug | 1985 |
Drug-induced changes in brain dopamine and their relation to parkinsonism.
Topics: Animals; Basal Ganglia; Brain; Cerebral Ventricles; Dihydroxyphenylalanine; Dopamine; Electric Stimu | 1970 |
The pharmacology of parkinsonism (a review).
Topics: Acetylcholine; Animals; Atropa belladonna; Atropine; Central Nervous System; Chlorpromazine; Dextroa | 1968 |
15 trials available for haloperidol and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Blood lactate levels in patients receiving first- or second- generation antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dopamine Antagonists; Drug Monitoring; Haloperidol; Hu | 2011 |
Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Bri | 2006 |
Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report.
Topics: Adult; Autonomic Nervous System; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; | 1984 |
Clinical evaluation of bromperidol versus haloperidol in psychotic patients.
Topics: Adult; Aged; Akathisia, Drug-Induced; Clinical Trials as Topic; Double-Blind Method; Drug Tolerance; | 1980 |
Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine.
Topics: Aged; Biperiden; Clinical Trials as Topic; Clozapine; Dibenzazepines; Drug Therapy, Combination; Dys | 1978 |
Parkinsonism by haloperidol and piribedil.
Topics: Adolescent; Adult; Clinical Trials as Topic; Female; Haloperidol; Humans; Male; Parkinson Disease, S | 1978 |
Implications of phenothiazine side effects: a study of antiparkinsonian agents in an older population.
Topics: Adult; Aged; Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic; Delayed-Action Preparat | 1975 |
Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients.
Topics: Adult; Aged; Basal Ganglia Diseases; Clinical Trials as Topic; Clozapine; Dibenzazepines; Haloperido | 1975 |
Side effects during long-term treatment with depot antipsychotic medication.
Topics: Akathisia, Drug-Induced; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced; | 1991 |
Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia.
Topics: Adult; Aged; Clopenthixol; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Human | 1991 |
Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Biperiden; Chlorprothixene; Dyskinesia, Drug-I | 1986 |
The use of benzodiazepines in the treatment of manic-depressive illness.
Topics: Acute Disease; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Basal Ga | 1988 |
Comparison of phenothiazine and nonphenothiazine neuroleptics according to psychopathology, side effects and computerized EEG.
Topics: Alpha Rhythm; Chronic Disease; Clinical Trials as Topic; Computers; Electroencephalography; Female; | 1974 |
Neuromuscular effects of long-term phenothiazine medication, electroconvulsive therapy and leucotomy.
Topics: Aged; Chlorpromazine; Clinical Trials as Topic; Electric Stimulation Therapy; Female; Haloperidol; H | 1966 |
Effects of L-DOPA on pharmacological parkinsonism.
Topics: Adolescent; Adult; Chlorpromazine; Clinical Trials as Topic; Dihydroxyphenylalanine; Female; Haloper | 1966 |
107 other studies available for haloperidol and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Topics: Animals; Antiparkinson Agents; Carbidopa; Catalepsy; Coumarins; Disease Models, Animal; Drug Combina | 2019 |
Systems pharmacology based approach to investigate the in-vivo therapeutic efficacy of Albizia lebbeck (L.) in experimental model of Parkinson's disease.
Topics: Albizzia; Animals; Behavior, Animal; Cerebral Cortex; Disease Models, Animal; Haloperidol; Motor Ski | 2019 |
Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease.
Topics: Administration, Intranasal; alpha-Synuclein; Animals; Blood-Brain Barrier; Cell Line, Tumor; Chitosa | 2020 |
Investigation of anti-Parkinson activity of dicyclomine.
Topics: Animals; Dicyclomine; Disease Models, Animal; Dopamine; Haloperidol; Mice; Paraquat; Parkinson Disea | 2022 |
Exploring the Therapeutic Potentials of Highly Selective Oxygenated Chalcone Based MAO-B Inhibitors in a Haloperidol-Induced Murine Model of Parkinson's Disease.
Topics: Animals; Brain; Catalepsy; Chalcones; Dopamine; Haloperidol; Mice; Monoamine Oxidase; Monoamine Oxid | 2020 |
Oral administration of haloperidol at clinically recommended doses elicits smaller parkinsonian effects but more tardive dyskinesia in rats.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Behavior, Animal; Dyskinesia, Drug-Induced; Exp | 2013 |
A severe and irreversible case of tardive rigid-akinetic parkinsonian syndrome: the role of the DaTscan.
Topics: Aged, 80 and over; Antipsychotic Agents; Brain; Diagnosis, Differential; Dopamine Plasma Membrane Tr | 2013 |
Reversal of haloperidol induced motor deficits in rats exposed to repeated immobilization stress.
Topics: Adaptation, Psychological; Animals; Brain; Disease Models, Animal; Haloperidol; Male; Motor Activity | 2014 |
Drug-induced parkinsonism following chronic methamphetamine use by a patient on haloperidol decanoate.
Topics: Adult; Amphetamine-Related Disorders; Diphenhydramine; Dose-Response Relationship, Drug; Drug Intera | 2015 |
Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.
Topics: Allosteric Regulation; Animals; Apomorphine; Benzhydryl Compounds; Catalepsy; Disease Models, Animal | 2010 |
Reversal of haloperidol-induced motor deficits by mianserin and mesulergine in rats.
Topics: Animals; Antipsychotic Agents; Catalepsy; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Ha | 2011 |
Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?
Topics: 3,4-Methylenedioxyamphetamine; Adrenergic Uptake Inhibitors; Animals; Catalepsy; Dopamine Antagonist | 2002 |
Schizophrenia. Management issues that complicate care of older persons.
Topics: Age Factors; Aged; Antipsychotic Agents; Cognition Disorders; Comorbidity; Haloperidol; Health Servi | 2002 |
Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease: implications for treating Parkinson's disease?
Topics: Adenosine Triphosphate; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Dose-Response | 2005 |
Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Chromatography, High Pressure Liquid; Cross | 2005 |
Using striatal dopamine transporter single photon emission computed tomography imaging to rule out Dementia with Lewy Bodies in elderly patients with antipsychotic-induced parkinsonism.
Topics: Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Cyclohexanols; Depressive Diso | 2007 |
Absorption and excretion of tritiated haloperidol in man. (A preliminary report).
Topics: Haloperidol; Humans; Parkinson Disease, Secondary; Schizophrenia; Tritium | 1967 |
[Effect of high single doses of bromocriptine in schizophrenic patients with elevated serum prolactin levels and extrapyramidal side effects associated with neuroleptic treatment (author's transl)].
Topics: Adult; Antipsychotic Agents; Bromocriptine; Chlorpromazine; Chronic Disease; Dose-Response Relations | 1980 |
Cerebrospinal fluid homovanillic acid patterns during neuroleptic treatment.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Female; Haloperidol; Homovanillic Acid; Humans; Male; P | 1981 |
Reversible drug-induced parkinsonism. Clinicopathologic study of two cases.
Topics: Aged; Antipsychotic Agents; Chlorpromazine; Haloperidol; Humans; Male; Middle Aged; Parkinson Diseas | 1982 |
A possible neurochemical basis for the neuropsychiatric aspects of baclofen therapy.
Topics: Adult; Baclofen; Bipolar Disorder; Brain; Delusions; Depressive Disorder; Dose-Response Relationship | 1983 |
Adverse drug reactions. An epidemiological study at psychiatric hospitals.
Topics: Adult; Amitriptyline; Drug Evaluation; Female; Germany, West; Haloperidol; Hospitals, Psychiatric; H | 1984 |
Development of tolerance to the therapeutic effect of amantadine on akathisia.
Topics: Adult; Akathisia, Drug-Induced; Amantadine; Bipolar Disorder; Drug Tolerance; Female; Haloperidol; H | 1984 |
[Extrapyramidal reactions and neuroleptic malignant syndrome].
Topics: Adult; Amantadine; Basal Ganglia Diseases; Dantrolene; Haloperidol; Humans; Male; Neuroleptic Malign | 1984 |
Effects of electroconvulsive therapy on mood, parkinsonism, and tardive dyskinesia in a depressed patient: ECT and dopamine systems.
Topics: Aged; Brain; Delusions; Depressive Disorder; Dopamine; Dyskinesia, Drug-Induced; Electroconvulsive T | 1983 |
Experimental pharmacological Parkinsonism (preliminary report).
Topics: Animals; Caudate Nucleus; Cell Membrane; Chloral Hydrate; Electrophoresis, Polyacrylamide Gel; Halop | 1983 |
The pharmacotherapy of Tourette syndrome.
Topics: Benztropine; Dyskinesia, Drug-Induced; Haloperidol; Humans; Parkinson Disease, Secondary; Tourette S | 1980 |
A mechanographic method for measurement of muscle tone in the conscious rat. The calf muscle stretch response in reserpine-induced rigidity.
Topics: Animals; Apomorphine; Biomechanical Phenomena; Disease Models, Animal; Haloperidol; Male; Muscle Con | 1982 |
Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics.
Topics: Adolescent; Adult; Age Factors; Aged; Antiparkinson Agents; Basal Ganglia Diseases; Drug Therapy, Co | 1982 |
N-Methyl-D-aspartate receptor participation in Parkinson's disease, a neurodegenerative disorder.
Topics: Animals; Antiparkinson Agents; Apomorphine; Benzazepines; Catalepsy; Dizocilpine Maleate; Haloperido | 1995 |
Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Drug Therapy, Combination; Haloperidol; Hum | 1995 |
Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperi | 1995 |
Selegiline for neuroleptic-induced parkinsonism.
Topics: Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Schizoph | 1993 |
Regulation by D2 dopamine receptors of in vivo dopamine synthesis in striata of rats and mice with experimental parkinsonism.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Corpus Striatum; Dihydroxyphenylalanine; Dopa | 1994 |
Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys.
Topics: Aggression; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Dopamine Agents; Haloperid | 1993 |
[The mechanism of the pathogenesis of drug-induced parkinsonism (experimental biochemical and bioelectrical research on the action of haloperidol)].
Topics: Animals; Behavior, Animal; Brain Chemistry; Caudate Nucleus; Dogs; Electroencephalography; Haloperid | 1993 |
Delirium associated with a combination of sertraline, haloperidol, and benztropine.
Topics: 1-Naphthylamine; Adult; Benztropine; Delirium; Depressive Disorder; Drug Interactions; Drug Therapy, | 1996 |
Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
Topics: Animals; Bacterial Proteins; Base Sequence; Benzazepines; Blotting, Western; Cabergoline; Corpus Str | 1996 |
Increase of serum creatine phosphokinase in catatonia: an investigation in 32 acute catatonic patients.
Topics: Acute Disease; Adult; Antipsychotic Agents; Catatonia; Combined Modality Therapy; Creatine Kinase; D | 1996 |
Drug-induced parkinsonism after allogeneic bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Female; Haloperidol; Humans; Levodopa; Parkinson Disease, Second | 1996 |
Adverse interaction of tacrine and haloperidol.
Topics: Aged; Dementia; Drug Interactions; Drug Therapy, Combination; Female; Haloperidol; Humans; Parkinson | 1996 |
Preservation of autoreceptor-mediated increases in dopamine synthesis in aged mice with experimentally-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Aromat | 1997 |
Absence of parkinsonism among patients in long-term neuroleptic therapy who abuse cocaine.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cocaine; Comorbidity; Delayed-Action Preparations; Flu | 1997 |
Extrapyramidal symptoms from intravenous haloperidol in the treatment of delirium.
Topics: Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Injections, Intravenous; Middle Aged; P | 1997 |
Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Brain; Brain Mapping; Dopamine Anta | 1997 |
Extrapyramidal side effects in patients with Alzheimer's disease treated with low-dose neuroleptic medication.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Antipsychotic Agents; Basal Gangli | 1998 |
Dopamine metabolism in the striatum of hemiparkinsonian model rats with dopaminergic grafts.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Brain Tissue Transplantation; Carrier Prot | 1998 |
Chronic haloperidol produces a time- and dose-related slowing of lick rhythm in rats: implications for rodent models of tardive dyskinesia and neuroleptic-induced parkinsonism.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, | 1998 |
Persistent loss of tyrosine hydroxylase immunoreactivity in the substantia nigra after neuroleptic withdrawal.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Dendrites; Female; Haloperidol; Humans; Male; P | 1998 |
[Multiple microinjections of haloperidol in rat globus pallidus induce vegetative components of parkinsonian syndrome].
Topics: Animals; Autonomic Nervous System; Avoidance Learning; Dopamine Antagonists; Globus Pallidus; Halope | 1998 |
Etiology of parkinsonism in a Brazilian movement disorders clinic.
Topics: Aged; Anti-Dyskinesia Agents; Brazil; Calcium Channel Blockers; Cinnarizine; Female; Flunarizine; Ha | 1998 |
Preventing contractures [correction of contractions] in neuroleptic malignant syndrome and dystonia.
Topics: Anti-Dyskinesia Agents; Botulinum Toxins; Combined Modality Therapy; Contracture; Dystonia; Female; | 1998 |
Biosynthesis of a parkinsonism-preventing substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline, is inhibited by parkinsonism-inducing compounds in rat brain mitochondrial fraction.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antipsychotic Agents; Biogenic Amines; Carbolines; Haloperidol | 1999 |
GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist.
Topics: Animals; Antiparkinson Agents; Binding, Competitive; Catalepsy; Cyclopentanes; Drug Evaluation, Prec | 1999 |
Interaction between olanzapine and haloperidol.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Drug Interactions; Haloperidol; Humans; Male; Olanzapin | 1999 |
L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats.
Topics: Animals; Anti-Dyskinesia Agents; Catalepsy; Dopamine Antagonists; Electromyography; Excitatory Amino | 1999 |
Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats.
Topics: alpha-Methyltyrosine; Animals; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; | 1999 |
Drug-induced dysphagia.
Topics: Aged; Antipsychotic Agents; Deglutition Disorders; Haloperidol; Humans; Male; Parkinson Disease, Sec | 1999 |
Effects of blockade of metabotropic glutamate receptors in the subthalamic nucleus on haloperidol-induced Parkinsonism in rats.
Topics: Animals; Benzoates; Dopamine Antagonists; Dystonia; Excitatory Amino Acid Antagonists; Glycine; Halo | 2000 |
Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Catal | 2000 |
Relationship between structure and drug-induced parkinsonism.
Topics: Antipsychotic Agents; Catalepsy; Cinnarizine; Drug Design; Flunarizine; Haloperidol; Humans; Parkins | 2000 |
Analysis of the metabolism of haloperidol (HP) and its neurotoxic pyridinium metabolite (HPP+) in patients with drug-induced parkinsonism.
Topics: Adult; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Halo | 2000 |
Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol.
Topics: Animals; Antiparkinson Agents; Apomorphine; Binding, Competitive; Brain Chemistry; Catalepsy; Dopami | 2000 |
Pharmacological involvement of the calcium channel blocker flunarizine in dopamine transmission at the striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Calcium Channel Blockers; Calcium Channels, L- | 2001 |
A new putative neuroregulator of the extrapyramidal system.
Topics: Animals; Dextroamphetamine; Extrapyramidal Tracts; Haloperidol; Humans; Male; Methyltyrosines; Neuro | 1978 |
[Pharmacopsychiatry and iatrogenic parkinsonism].
Topics: Antiparkinson Agents; Antipsychotic Agents; Clozapine; Haloperidol; Humans; Parkinson Disease; Parki | 1978 |
Fluphenazine enanthate in the outpatient treatment of late paraphrenia.
Topics: Aged; Ambulatory Care; Delayed-Action Preparations; Female; Fluphenazine; Haloperidol; Humans; Injec | 1979 |
[Cerebral degenerative change in association with dyskinesia following neuroleptic treatment (author's transl)].
Topics: Female; Haloperidol; Humans; Middle Aged; Movement Disorders; Parkinson Disease; Parkinson Disease, | 1978 |
Haloperidol-induced tardive dyskinesia in monkeys.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Haloperidol; Haplorhini; Macaca f | 1976 |
Coexisting tardive dyskinesia and parkinsonism: a case report.
Topics: Acetylcholine; Adult; Benztropine; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Fluphenazine | 1977 |
Catatonic reactions to high-potency neuroleptic drugs.
Topics: Adolescent; Adult; Amantadine; Catatonia; Dose-Response Relationship, Drug; Female; Fluphenazine; Ha | 1977 |
Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol.
Topics: Adult; Female; Hallucinations; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mal | 1976 |
Clinical and biochemical parameters during neuroleptic treatment. II. Antipsychotic effect of haloperidol in patients with chronic organic brain damage.
Topics: Adult; Aged; Brain Damage, Chronic; Depression; Female; Hallucinations; Haloperidol; Homovanillic Ac | 1976 |
Haloperidol update: 1975.
Topics: Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Haloperidol; Humans; Mental Disorders; Parkinson D | 1976 |
[Preconvulsive state and hyperfunction of the striatum (clinico-experimental findings)].
Topics: Adolescent; Adult; Aged; Animals; Apomorphine; Convulsants; Corpus Striatum; Electroencephalography; | 1976 |
Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzothiazoles; Corpus Striatum; Dihydroxyphenylalanine; Do | 1992 |
Haloperidol-induced dystonia and parkinsonism on discontinuing metoclopramide: implications for differential thalamocortical activity.
Topics: Adult; Brain; Drug Therapy, Combination; Dystonia; Female; Haloperidol; Humans; Metoclopramide; Park | 1992 |
Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: possible relation to parkinsonian symptoms.
Topics: Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Eating; Feeding and Eating | 1991 |
Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Biotransformatio | 1991 |
Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys.
Topics: Animals; Antipsychotic Agents; Arousal; Benzamides; Cebus; Disease Models, Animal; Dyskinesia, Drug- | 1990 |
Neurologic approach to drug-induced movement disorders: a study of 125 patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amitriptyline; Antipsychotic Agents; Chorea | 1990 |
Disappearance of a putative DA-neuron antibody following adrenal medulla transplantation: relationship to a striatal-derived DA neuron trophic factor.
Topics: Adrenal Gland Neoplasms; Adrenal Medulla; Animals; Autoantibodies; Cells, Cultured; Cerebellum; Corp | 1990 |
A new rodent model for neuroleptic-induced pseudo-parkinsonism: low doses of haloperidol increase forelimb tremor in the rat.
Topics: Animals; Atropine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induce | 1990 |
Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine.
Topics: Adult; Aged; Female; Haloperidol; Humans; Male; Middle Aged; Orphenadrine; Parkinson Disease, Second | 1989 |
Cerebrospinal fluid homovanillic acid and hypokinetic side effects of neuroleptics.
Topics: Acetylcholine; Adolescent; Adult; Antipsychotic Agents; Catatonia; Chlorpromazine; Dopamine; Female; | 1985 |
Visual contrast sensitivity in drug-induced Parkinsonism.
Topics: Adolescent; Adult; Bipolar Disorder; Depressive Disorder; Drug Therapy, Combination; Female; Fluspir | 1989 |
Catatonic reaction to accidental haloperidol overdose: an unrecognized drug abuse risk.
Topics: Adult; Catatonia; Haloperidol; Humans; Male; Parkinson Disease, Secondary; Substance-Related Disorde | 1986 |
Extrapyramidal reactions to prochlorperazine and haloperidol in the United Kingdom.
Topics: Adolescent; Adult; Age Factors; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Dystonia; Female; | 1986 |
Pseudorheumatoid deformity of the feet associated with parkinsonism.
Topics: Female; Foot Deformities, Acquired; Haloperidol; Humans; Middle Aged; Parkinson Disease, Secondary | 1986 |
Neuroleptic-induced parkinsonism increases with repeated treatment in monkeys.
Topics: Animals; Cebus; Haloperidol; Parkinson Disease, Secondary; Time Factors | 1987 |
Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol.
Topics: Adolescent; Adult; Age Factors; Aged; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle A | 1986 |
Absence of age effect on plasma haloperidol neuroleptic levels in psychiatric patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aging; Female; Haloperidol; Humans; Male; Middle Aged | 1985 |
Persistent drug-induced parkinsonism.
Topics: Bipolar Disorder; Haloperidol; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Risk | 1985 |
Propranolol-induced tardive dyskinesia in a patient with akathisia.
Topics: Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Middle Aged; Parkinson Disease, Secondary; Pr | 1985 |
[Comparative biochemical studies in organic parkinsonian syndromes and drug induced parkinsonian syndromes].
Topics: Alanine Transaminase; Aspartate Aminotransferases; Biochemical Phenomena; Biochemistry; Chlorpromazi | 1966 |
[Study of extrapyramidal manifestations induced by neuroleptics].
Topics: Antiparkinson Agents; Chlorpromazine; Drug Synergism; Extrapyramidal Tracts; Fluphenazine; Haloperid | 1972 |
Letter: Withdrawal syndrome after neuroleptics.
Topics: Adult; Chlorpromazine; Haloperidol; Humans; Male; Parkinson Disease, Secondary; Substance Withdrawal | 1973 |
Effect of drugs used in psychoses on cerebral dopamine metabolism.
Topics: Animals; Atropine; Brain; Butyrophenones; Cats; Chlorpromazine; Dogs; Dopamine; Female; Haloperidol; | 1970 |
[Pharmacological properties of 6,6,9-trimethyl-9-azabicyclo (3,3,1)non-3 beta-yl-alpha, alpha-di(2-thienyl) glycolate hydrochloride monohydrate (PG-501), a new anti-parkinsonian agent].
Topics: Acetylcholine; Analgesics; Anesthetics, Local; Animals; Anticonvulsants; Barbiturates; Behavior, Ani | 1971 |
[Persisting extrapyramidal syndrome following neuroleptic therapy].
Topics: Amines; Brain; Dopamine; Extrapyramidal Tracts; Haloperidol; Humans; Parkinson Disease; Parkinson Di | 1969 |
[On the results of treatment and complications during the use of haloperidol in patients with long-term schizophrenia].
Topics: Adult; Blood Pressure; Cardiovascular Diseases; Catatonia; Chlorpromazine; Cognition Disorders; Hall | 1969 |
Pink spot--is it a drug artefact?
Topics: Amitriptyline; Amobarbital; Chlorpromazine; Chromatography; Haloperidol; Humans; Mental Disorders; P | 1970 |
[Haloperidol in the treatment of hyperkinetic syndromes].
Topics: Adult; Aged; Chorea; Female; Haloperidol; Humans; Male; Middle Aged; Movement Disorders; Parkinson D | 1970 |
[The effect of phenamine on medicinal parkinsonism and retardation of movement upon stimulation of the caudate nucleus (a clinico-experimental study)].
Topics: Amphetamine; Caudate Nucleus; Female; Haloperidol; Humans; Male; Parkinson Disease; Parkinson Diseas | 1970 |
[Joint clinical study of a long term neuroleptic drug fluspirilene].
Topics: Affective Symptoms; Delayed-Action Preparations; Haloperidol; Humans; Injections, Intramuscular; Par | 1970 |
Haloperidol and thioridazine in treatment of chronic schizophrenics.
Topics: Female; Haloperidol; Humans; Male; Parkinson Disease, Secondary; Schizophrenia; Thioridazine | 1966 |
A controlled trial of anti-Parkinson drugs in drug-induced Parkinsonism.
Topics: Adolescent; Adult; Chlorpromazine; Haloperidol; Humans; Middle Aged; Orphenadrine; Parasympatholytic | 1966 |